Calithera Biosciences, Inc. (CALA) Upgraded to Sell at BidaskClub
Calithera Biosciences, Inc. (NASDAQ:CALA) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Friday.
A number of other equities research analysts have also weighed in on CALA. Zacks Investment Research lowered Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, May 12th. Wells Fargo & Company restated an “outperform” rating and set a $20.00 price objective (up previously from $15.00) on shares of Calithera Biosciences in a research note on Tuesday, June 6th. Finally, HC Wainwright restated a “buy” rating and set a $19.00 price objective (up previously from $14.00) on shares of Calithera Biosciences in a research note on Monday, June 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $15.50.
Shares of Calithera Biosciences (CALA) traded up 0.36% during trading on Friday, hitting $14.00. The stock had a trading volume of 331,207 shares. The stock has a 50-day moving average of $15.74 and a 200 day moving average of $13.06. Calithera Biosciences has a 12-month low of $2.20 and a 12-month high of $20.05. The firm’s market cap is $496.66 million.
Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.14. The business had revenue of $7.26 million for the quarter, compared to analyst estimates of $4.80 million. On average, analysts predict that Calithera Biosciences will post ($0.83) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Calithera Biosciences, Inc. (CALA) Upgraded to Sell at BidaskClub” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/19/calithera-biosciences-inc-cala-upgraded-to-sell-at-bidaskclub.html.
In other Calithera Biosciences news, VP Keith Orford sold 2,120 shares of the stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $18.31, for a total transaction of $38,817.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 16.30% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Laurion Capital Management LP purchased a new position in Calithera Biosciences during the first quarter worth approximately $504,000. FMR LLC increased its position in Calithera Biosciences by 278.2% in the first quarter. FMR LLC now owns 1,462,190 shares of the biotechnology company’s stock worth $16,888,000 after buying an additional 1,075,592 shares in the last quarter. Wellington Management Group LLP purchased a new position in Calithera Biosciences during the first quarter worth approximately $47,550,000. United Services Automobile Association purchased a new position in Calithera Biosciences during the first quarter worth approximately $342,000. Finally, ClariVest Asset Management LLC purchased a new position in Calithera Biosciences during the first quarter worth approximately $194,000. 55.11% of the stock is currently owned by institutional investors.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.